Stay updated on Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Sign up to get notified when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.

Latest updates to the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the usual study details and navigation for NCT03851588. This indicates an access restriction to the record rather than a content update on the study page.SummaryDifference20%

- Check36 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6 on the page, indicating a software version update without changes to trial information.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page’s version label was updated from Revision: v3.6.4 to Revision: v3.6.5. This is a minor release tag update rather than a modification to the study content or layout.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page now displays a newer site revision, updating from v3.6.3 to v3.6.4, indicating a software deployment. The update is limited to system metadata and does not modify study content or user-facing features.SummaryDifference0.1%

- Check93 days agoChange DetectedFooter shows Revision: v3.6.3, replacing v3.6.2, representing a small behind-the-scenes update to the site.SummaryDifference0.1%

- Check100 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, indicating a newer build of the page. This is a backend/version change rather than content-level updates.SummaryDifference0.1%

Stay in the know with updates to Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.